according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 6.0 04/14/2025 1714262-00024 Date of first issue: 05/25/2017

SECTION 1. IDENTIFICATION

Product name : Embutramide / Mebezonium / Tetracaine Formulation

Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 37 McCarville Street

Charlottetown, PE C1E 2A7

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Flammable liquids : Category 4

Acute toxicity (Oral) : Category 4

Acute toxicity (Inhalation) : Category 4

Acute toxicity (Dermal) : Category 4

Eye irritation : Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity

- single exposure

Category 2 (Nervous system, muscle)

Specific target organ toxicity

- single exposure

Category 3

GHS label elements

Hazard pictograms :





Signal Word : Danger

Hazard Statements : H227 Combustible liquid.

H302 + H312 + H332 Harmful if swallowed, in contact with skin

or if inhaled.

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 6.0 04/14/2025 1714262-00024 Date of first issue: 05/25/2017

H319 Causes serious eye irritation. H336 May cause drowsiness or dizziness. H360D May damage the unborn child.

H371 May cause damage to organs (Nervous system, muscle).

Precautionary Statements

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.

P260 Do not breathe mist or vapors.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel unwell. Rinse mouth.

P302 + P352 + P312 IF ON SKIN: Wash with plenty of soap and water. Call a doctor if you feel unwell.

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a doctor if you feel unwell.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P308 + P311 IF exposed or concerned: Call a doctor.

P337 + P313 If eye irritation persists: Get medical attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Vapors may form explosive mixture with air.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

	Common Name/Synonym	CAS-No.	Concentration (% w/w)
N,N-	Formic acid	68-12-2	>= 30 - < 60 *

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 04/14/2025 1714262-00024 Date of first issue: 05/25/2017 6.0

Dimethylformamide	dimethylamide		
Embutramide	No data availa- ble	15687-14-6	>= 10 - < 30 *
Mebezonium iodide	No data availa- ble	7681-78-9	>= 5 - < 10 *
tetracaine hydrochlo- ride	No data availa- ble	136-47-0	>= 0.1 - < 1 *

Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of contact, immediately flush skin with plenty of water. In case of skin contact

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed, DO NOT induce vomiting. If swallowed

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person. Harmful if swallowed, in contact with skin or if inhaled.

Most important symptoms and effects, both acute and

Causes serious eve irritation.

May cause drowsiness or dizziness.

May damage the unborn child. May cause damage to organs.

First Aid responders should pay attention to self-protection, Protection of first-aiders

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

delayed

High volume water jet

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 04/14/2025 1714262-00024 Date of first issue: 05/25/2017 6.0

Specific hazards during fire

fighting

Do not use a solid water stream as it may scatter and spread

fire.

Flash back possible over considerable distance. Vapors may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Remove all sources of ignition. Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Non-sparking tools should be used.

Soak up with inert absorbent material.

Suppress (knock down) gases/vapors/mists with a water spray

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 6.0 04/14/2025 1714262-00024 Date of first issue: 05/25/2017

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapors.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Keep away from heat, hot surfaces, sparks, open flames and

other ignition sources. No smoking.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Keep in a cool, well-ventilated place.

Store in accordance with the particular national regulations.

Keep away from heat and sources of ignition.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
N,N-Dimethylformamide	68-12-2	TWA	10 ppm 30 mg/m³	CA AB OEL
		TWA	5 ppm	CA BC OEL
		TWAEV	5 ppm	CA QC OEL
		TWA	5 ppm	ACGIH
Embutramide	15687-14-6	TWA	10 μg/m3 (OEB 3)	Internal
		STEL	30 μg/m3	Internal
		Wipe limit	100 µg/100 cm ²	Internal

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 6.0 04/14/2025 1714262-00024 Date of first issue: 05/25/2017

Mebezonium iodide	7681-78-9	TWA	1 μg/m3 (OEB 4)	Internal		
		STEL	3 µg/m3 (OEB 4)	Internal		
		Wipe limit	10 μg/100 cm2	Internal		
tetracaine hydrochloride	136-47-0	TWA	5 μg/m3 (OEB 4)	Internal		
	Further inforr	Further information: DSEN, Skin				
		Wipe limit	50 μg/100 cm ²	Internal		

Biological occupational exposure limits

Components	CAS-No.	Control parameters	Biological specimen	Sam- pling time	Permissible concentration	Basis
N,N-Dimethylformamide	68-12-2	Total N- Methylforma mide	Urine	End of shift (As soon as possible after exposure ceases)	30 mg/l	ACGIH BEI
		N-Acetyl-S- (N- methylcarba moyl) cysteine	Urine	End of shift at end of work- week	30 mg/l	ACGIH BEI

Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates, ammonia/amines and organic vapor

6/18

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 6.0 04/14/2025 1714262-00024 Date of first issue: 05/25/2017

type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving. Take note that the product is

flammable, which may impact the selection of hand

protection.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : 5-6

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : 81 °C

Evaporation rate : No data available

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 04/14/2025 1714262-00024 Date of first issue: 05/25/2017 6.0

Flammability (solid, gas) Not applicable

Flammability (liquids) Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure No data available

Relative vapor density No data available

Relative density No data available

Density No data available

Solubility(ies)

Water solubility soluble

Partition coefficient: n-

octanol/water

No data available

Autoignition temperature No data available

Decomposition temperature No data available

Viscosity

No data available Viscosity, kinematic

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight Not applicable

Particle characteristics

Particle size Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Stable under normal conditions. Chemical stability

Possibility of hazardous reac-

Combustible liquid.

Vapors may form explosive mixture with air. tions

Can react with strong oxidizing agents.

Conditions to avoid Heat, flames and sparks.

Incompatible materials Oxidizing agents

Hazardous decomposition No hazardous decomposition products are known.

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 6.0 04/14/2025 1714262-00024 Date of first issue: 05/25/2017

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Harmful if swallowed, in contact with skin or if inhaled.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,224 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 19.41 mg/l

Exposure time: 4 h
Test atmosphere: vapor
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: 1,942 mg/kg

Method: Calculation method

Components:

N,N-Dimethylformamide:

Acute oral toxicity : LD50 (Rat): 3,010 mg/kg

Acute inhalation toxicity

Acute toxicity estimate: 11 mg/l

Exposure time: 4 h
Test atmosphere: vapor
Method: Expert judgment

Remarks: Based on national or regional regulation.

Acute dermal toxicity :

Acute toxicity estimate: 1,100 mg/kg

Method: Expert judgment

Remarks: Based on national or regional regulation.

Embutramide:

Acute oral toxicity : LD50 (Rat): 1,550 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Dog): 31 mg/kg

Application Route: Intravenous

TDLo (Dog): 15.5 mg/kg Application Route: Intravenous

Symptoms: narcosis

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version 6.0

Revision Date: 04/14/2025

SDS Number: 1714262-00024 Date of last issue: 12/04/2024 Date of first issue: 05/25/2017

LD50 (Horse): 20 mg/kg

Application Route: Intravenous

LD50 (sheep): 80 mg/kg Application Route: Intravenous

LD50 (Pig): 100 mg/kg

Application Route: Intravenous

Mebezonium iodide:

Acute oral toxicity : LD50 (Rat, female): 200 - 300 mg/kg

Acute toxicity (other routes of : LC50 (Dog): 15 mg/kg

administration)

Application Route: Intravenous

tetracaine hydrochloride:

Acute toxicity (other routes of : LD50 (Rat): 6 mg/kg

administration)

Application Route: Intravenous

LD50 (Mouse): 6 mg/kg

Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Components:

N,N-Dimethylformamide:

Species Rabbit

Result No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

N,N-Dimethylformamide:

Species Rabbit

Result Irritation to eyes, reversing within 21 days

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 6.0 04/14/2025 1714262-00024 Date of first issue: 05/25/2017

Components:

N,N-Dimethylformamide:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact
Species : Mouse
Result : negative

tetracaine hydrochloride:

Routes of exposure : Dermal Result : Sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

N,N-Dimethylformamide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Test Type: Rodent dominant lethal test (germ cell) (in vivo)

Species: Rat

Application Route: inhalation (vapor)

Result: negative

Test Type: Rodent dominant lethal test (germ cell) (in vivo)

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

tetracaine hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 04/14/2025 1714262-00024 Date of first issue: 05/25/2017 6.0

Test Type: Chromosomal aberration

Result: equivocal

Genotoxicity in vivo Test Type: Micronucleus test

> Species: Rat Result: negative

Carcinogenicity

Not classified based on available information.

Components:

N,N-Dimethylformamide:

Species : Rat

Application Route : inhalation (vapor)

Exposure time

2 YearsOECD Test Guideline 451 Method

Result : negative

Species Mouse

Application Route inhalation (vapor) :

Exposure time 18 Months

: OECD Test Guideline 451 Method

Result : negative

Reproductive toxicity

May damage the unborn child.

Components:

N,N-Dimethylformamide:

Test Type: Two-generation study Effects on fertility

Species: Mouse

Application Route: Ingestion

Result: negative

Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Skin contact

Result: negative

Effects on fetal development Test Type: Embryo-fetal development

Species: Rabbit

Application Route: inhalation (vapor) Method: OECD Test Guideline 414

Result: positive

Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Skin contact Method: OECD Test Guideline 414

Result: positive

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 6.0 04/14/2025 1714262-00024 Date of first issue: 05/25/2017

Reproductive toxicity - As-

sessment

: Clear evidence of adverse effects on development, based on

animal experiments.

tetracaine hydrochloride:

Effects on fertility : Test Type: Fertility

Species: Rat, male and female Application Route: Subcutaneous Fertility: NOAEL: 7.5 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: NOAEL: 5 mg/kg body weight

Result: No teratogenic effects.

Test Type: Development

Species: Rabbit

Application Route: Subcutaneous

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: No teratogenic effects.

STOT-single exposure

May cause drowsiness or dizziness.

May cause damage to organs (Nervous system, muscle).

Components:

Embutramide:

Assessment : May cause drowsiness or dizziness.

Mebezonium iodide:

Target Organs : Nervous system, muscle
Assessment : May cause damage to organs.

tetracaine hydrochloride:

Target Organs : Central nervous system, Cardio-vascular system

Assessment : Causes damage to organs.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

N,N-Dimethylformamide:

Species : Rat NOAEL : 238 mg/kg

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 04/14/2025 1714262-00024 Date of first issue: 05/25/2017 6.0

LOAEL : 475 mg/kg Application Route Ingestion Exposure time 28 Days

Species Rat NOAEL 0.08 mg/l LOAEL 0.3 mg/l

Application Route : inhalation (vapor)

Exposure time 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Embutramide:

Inhalation Target Organs: Central nervous system

Symptoms: Drowsiness, Central nervous system depression,

muscle weakness. Shortness of breath

Mebezonium iodide:

Inhalation : Symptoms: Weakness, Fatigue, Breathing difficulties

tetracaine hydrochloride:

Inhalation Target Organs: Cardio-vascular system

Target Organs: Central nervous system

Symptoms: Central nervous system depression, Dizziness,

Headache, hypotension, Vomiting : Symptoms: Redness, pruritis

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Skin contact

Components:

N,N-Dimethylformamide:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 7,100 mg/l

Exposure time: 96 h

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 13,100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

: ErC50 (Desmodesmus subspicatus (green algae)): > 1,000

mg/l

Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): > 1,000

Exposure time: 72 h

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 04/14/2025 1714262-00024 Date of first issue: 05/25/2017 6.0

aquatic invertebrates (Chron-

ic toxicity)

Toxicity to daphnia and other : NOEC (Daphnia magna (Water flea)): 1,500 mg/l

Exposure time: 21 d

Embutramide:

Toxicity to fish : LC50: 21 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

: EC50: > 1,000 mg/l Toxicity to microorganisms

Exposure time: 24 h

Test Type: Respiration inhibition of activated sludge

Method: OECD Test Guideline 209

Persistence and degradability

Components:

N,N-Dimethylformamide:

Biodegradability Result: Readily biodegradable.

Biodegradation: 100 % Exposure time: 21 d

Method: OECD Test Guideline 301E

Bioaccumulative potential

Components:

N,N-Dimethylformamide:

Bioaccumulation : Species: Cyprinus carpio (Carp)

Bioconcentration factor (BCF): 0.3 - 1.2 Method: OECD Test Guideline 305C

Partition coefficient: n-

octanol/water

: log Pow: -0.93

Remarks: Calculation

Mobility in soil No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Empty containers should be taken to an approved waste Contaminated packaging

handling site for recycling or disposal.

Empty containers retain residue and can be dangerous.

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 6.0 04/14/2025 1714262-00024 Date of first issue: 05/25/2017

Do not pressurize, cut, weld, braze, solder, drill, grind, or expose such containers to heat, flame, sparks, or other sources of ignition. They may explode and cause injury and/or

death.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

ACGIH / TWA : 8-hour, time-weighted average

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 04/14/2025 1714262-00024 Date of first issue: 05/25/2017 6.0

CA AB OEL / TWA 8-hour Occupational exposure limit CA BC OEL / TWA 8-hour time weighted average :

: CA QC OEL / TWAEV Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant: DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation. Authorisation and Restriction of Chemicals: SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to

compile the Material Safety **Data Sheet**

Revision Date 04/14/2025 Date format mm/dd/yyyy

: Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific

according to the Hazardous Products Regulations



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024 6.0 04/14/2025 1714262-00024 Date of first issue: 05/25/2017

context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8